Leading developer of antibodies and antibody-based products selects clinivation WorldView® as their enterprise solution for on-demand global regulatory intelligence.
Natick, MA, October 10, 2008 – clinivation, Inc. announced today that BioPorto Diagnostics has selected the clinivation WorldView® enterprise solution for On-Demand Global Regulatory Intelligence.
“BioPorto is an innovative global leader in antibody research, and we are pleased that they have chosen clinivation WorldView® for comprehensive, authoritative, and up-to-date global regulatory intelligence,” said Richard Morroney, R.A.C., C.Q.A., clinivation’s Vice President of Quality and Regulatory Solutions.
About clinivation WorldView® On-Demand Global Regulatory Intelligence
Clinivation WorldView® is the medical device and diagnostic industry’s most comprehensive, authoritative, and up-to-date enterprise solution for On-Demand Global Regulatory Intelligence. Providing clear, step-by-step market clearance regulations, processes, and guidance for >99% of the world markets, only clinivation WorldView® delivers tried-and-true intelligence from certified, practicing professionals with real-world experience.
About BioPorto Diagnostics
Headquartered in Denmark, BioPorto Diagnostics develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. BioPorto’s developments include a test (NGAL) to diagnose and monitor acute kidney damage. BioPorto’s strategy is to develop new methods based on its antibody portfolio that can be patented and achieve a wide use in the diagnosis of various diseases.
For more information, please visit www.antibodyshop.com.